AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
1.230
+0.175 (16.59%)
Feb 5, 2026, 2:13 PM EST - Market open
AIM ImmunoTech Revenue
AIM ImmunoTech had revenue of $26.00K in the quarter ending September 30, 2025, a decrease of -25.71%. This brings the company's revenue in the last twelve months to $112.00K, down -41.05% year-over-year. In the year 2024, AIM ImmunoTech had annual revenue of $170.00K, down -15.84%.
Revenue (ttm)
$112.00K
Revenue Growth
-41.05%
P/S Ratio
9.96
Revenue / Employee
$4,870
Employees
23
Market Cap
3.51M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 170.00K | -32.00K | -15.84% |
| Dec 31, 2023 | 202.00K | 61.00K | 43.26% |
| Dec 31, 2022 | 141.00K | 6.00K | 4.44% |
| Dec 31, 2021 | 135.00K | -28.00K | -17.18% |
| Dec 31, 2020 | 163.00K | 23.00K | 16.43% |
| Dec 31, 2019 | 140.00K | -227.00K | -61.85% |
| Dec 31, 2018 | 367.00K | -70.00K | -16.02% |
| Dec 31, 2017 | 437.00K | 345.00K | 375.00% |
| Dec 31, 2016 | 92.00K | -41.00K | -30.83% |
| Dec 31, 2015 | 133.00K | -64.00K | -32.49% |
| Dec 31, 2014 | 197.00K | 47.00K | 31.33% |
| Dec 31, 2013 | 150.00K | -63.00K | -29.58% |
| Dec 31, 2012 | 213.00K | 52.00K | 32.30% |
| Dec 31, 2011 | 161.00K | 26.00K | 19.26% |
| Dec 31, 2010 | 135.00K | 24.00K | 21.62% |
| Dec 31, 2009 | 111.00K | -154.00K | -58.11% |
| Dec 31, 2008 | 265.00K | -794.00K | -74.98% |
| Dec 31, 2007 | 1.06M | 126.00K | 13.50% |
| Dec 31, 2006 | 933.00K | -150.00K | -13.85% |
| Dec 31, 2005 | 1.08M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 11.79M |
| SciSparc | 1.31M |
| Scinai Immunotherapeutics | 1.15M |
| Lyra Therapeutics | 600.00K |
| HCW Biologics | 422.03K |
AIM News
- 5 hours ago - AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer - GlobeNewsWire
- 13 days ago - AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering - GlobeNewsWire
- 2 months ago - AIM ImmunoTech to Participate in Live ‘Fireside' Chat on Virtual Investor Closing Bell Series - GlobeNewsWire
- 2 months ago - AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program - GlobeNewsWire
- 3 months ago - Aimia Inc. (AIM:CA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer - GlobeNewsWire
- 3 months ago - AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting - GlobeNewsWire
- 3 months ago - AIM ImmunoTech to Attend the 2025 Maxim Growth Summit - GlobeNewsWire